|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
16 September 2019 |
|
Main ID: |
ChiCTR1900025894 |
|
Date of registration:
|
2019-09-12 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease
|
|
Scientific title:
|
Parallel randomized controlled trial for Shengyang Yiwei Granule in the treatment of early Parkinson's disease |
|
Date of first enrolment:
|
2019-09-11 |
|
Target sample size:
|
experimental group:45;control group:23; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=43266 |
|
Study type:
|
Interventional study |
|
Study design:
|
Parallel
|
|
Phase:
|
0
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Kaida Wang
|
|
Address:
|
1 Jingba Road, Ji'nan, Shandong
|
|
Telephone:
|
+86 13854115876 |
|
Email:
|
baoyushou3@163.com |
|
Affiliation:
|
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
|
|
Name:
|
Kaida Wang
|
|
Address:
|
1 Jingba Road, Ji'nan, Shandong
|
|
Telephone:
|
+86 13854115876 |
|
Email:
|
baoyushou3@163.com |
|
Affiliation:
|
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: (1) Those who meet the diagnostic criteria of PD Chinese and Western medicine;
(2) TCM syndrome differentiation belongs to spleen and lung deficiency;
(3) Those aged 55-80 years;
(4) Modified HY stage <= 2.5;
(5) Conscious, vital signs are stable;
(6) Those who voluntarily accept this experimental study and informed consent.
Exclusion criteria: (1) Parkinson's syndrome and Parkinson's superposition syndrome caused by various causes such as cerebrovascular disease and poisoning;
(2) Those with major diseases such as severe liver and kidney, blood, tumor, endocrine disease or pain
(3) Those who are involved in other drug clinical trials;
(4) Psychiatric patients;
(5) Those who have a history of ugly drinking or a history of drug abuse.
Age minimum:
Age maximum:
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
parkinson disease
|
|
Intervention(s)
|
|
experimental group:Parkinson's disease routine medication, plus Shengyang Yiwei granules, water blunt, one dose, morning and evening;control group:Parkinson's disease routine medication, add Buzhong Yiqi granules, water blunt, one dose, morning and evening;
|
|
Primary Outcome(s)
|
|
Unified Parkinson's Disease Rating Scale (UPDRSI II III);Parkinson's Non-motor syndrome Scale (NMSS);
|
|
Source(s) of Monetary Support
|
|
Doctoral training fund
|
|
Ethics review
|
Status: Not approved
Approval date: 26/08/2013
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|